Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma appoints Zelboraf scientist as CMO

Keith Nolop joins US cancer biotech from Plexxikon

Kite Pharma Keith NolopDr Keith Nolop, one of the chief scientists behind the development of Roche's personalised skin cancer drug Zelboraf, has been appointed chief medical officer of cancer specialist Kite Pharma.

Dr Nolop joins the US-based biotech from Plexxikon, where he served as senior VP and chief medical officer since 2004.

During this time, he was clinical lead for the development of Zelboraf (vemurafenib), which was co-developed by Roche and is predicted to reach peak-year sales of $1bn to $1.5bn after approvals in the US and EU.

At Plexxikon, he also led the filing of eight investigational New Drug Applications in cancer.

Prior to joining Plexxikon, Dr Nolop was VP of clinical research at CoTherix, where he led the development and US approval for Ventavis (iloprost) to treat pulmonary arterial hypertension (PAH).

He also spent 11 years at Schering-Plough, serving as clinical lead for three drug approvals.

"Dr Nolop's vast experience in drug development from conception to approval will be instrumental to advancing Kite's eACT products through multi-center clinical trials and on to registration," said Dr Aya Jakobovits, president and CEO of Kite Pharma.

"We are very pleased to welcome him to the Kite management team."

4th June 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aurora Healthcare Communications

We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....